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Abstract
 Background—Both family history of dementia (FHD) and lower levels of Aβ-42 are 
indepentently associated with worse neurocognitive functioning in HIV-infected patients.
 Objective—To examine the relationships between cerebrospinal fluid (CSF) Aβ-42 and FHD 
with HIV-associated neurocognitive disorders (HAND).
 Methods—One hundred eighty-three HIV+ adults underwent neuropsychological and 
neuromedical assessments, and determination of CSF Aβ-42 concentration and FHD (defined as a 
self-reported first or second-degree relative with a dementia diagnosis). Univariate analyses and 
multivariable logistic regressions were used.
 Results—FHD was not associated with HAND (p = 0.24); however, CSF Aβ-42 levels were 
lower (p = 0.03) in the HAND group, but were not associated with FHD (p = 0.89). Multivariable 
models showed a main effect of CSF Aβ-42 (p = 0.03) and a trend-level (p = 0.06) interaction 
between FHD and CSF Aβ-42, such that lower CSF Aβ-42 was associated with HAND in those 
with FHD (p < 0.01) compared to those without FHD (p = 0.83). An analysis in those with follow-
up data showed that higher baseline CSF Aβ-42 was associated with lower risk of neurocognitive 
decline (p = 0.02). While we did not find an FHD X CSF Aβ-42 interaction (p = 0.83), when 
analyses were stratified by FHD, lower CSF Aβ-42 was associated at the trend-level with 
neurocognitive decline in the FHD group (p = 0.08) compared to the no FHD group (p = 0.15).
 Conclusions—FHD moderates the relationship between of CSF Aβ-42 and HAND. The 
findings highlight the complexities in interpreting the relationships between biomarkers of age-
related neurodegeneration and HAND.
Keywords
HIV; dementia; biomarkers; cerebrospinal fluid; family history; neurocognitive impairment
 1. INTRODUCTION
Combination antiretroviral therapy (ART) has decreased the incidence of HIV-associated 
dementia (HAD) [1 – 6], however, the prevalence of milder forms of HIV-associated 
neurocognitive disorders (HAND) remains high [1,4,6 – 8]. Thus, isolating factors that 
predict neurocognitive (NC) impairment in HIV is an important research area.
HIV-induced damage to neurons can be mediated through indirect neurotoxic mechanisms 
and is associated with NC impairment [9 – 11]. Commonly described morphologic 
correlates of HAND are synaptodendritic damage, astrocytosis, and microgliosis [12 – 15]. 
Other neuropathologies have also been described [16 – 19], including β-amyloid deposition 
in HIV-infected persons [16,18]. As such, cerebrospinal fluid (CSF) measurements of 
amyloid may be helpful in identifying risk for HAND. In this way, low CSF Aβ-42 levels 
(amyloid beta-protein ending at amino acid position 42) are considered pathologic, as low 
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levels indicate β-amyloid is being deposited elsewhere (i.e., the brain). Studies have noted 
CSF Aβ-42 concentrations in HAND patients similar to those of Alzheimer’s disease (AD) 
patients, supporting this biomarker as a proxy for neuropathology [20 – 21]. There is also 
some evidence for neuroprotective therapies in reversing Aβ-42 neuronal toxicity in HAND 
[22 – 23].
Given that neurodegenerative diseases, such as AD, can be partially inherited, examining 
family history of dementia (FHD) may be a useful and feasible approach for identifying and 
predicting those HIV+ individuals who may have a predisposition for NC impairment. 
Furthermore, gathering FHD may capture familial neurodegenerative conditions for which 
genetic correlates or screenings are not available. A study in adults with HIV found that 
those who reported a FHD had poorer cognitive performance [24], however no biomarkers 
were examined in that study.
Thus, we sought to examine the associations between CSF levels of Aβ-42, FHD, and 
HAND. The specific objectives were: 1) to assess whether FHD was associated with CSF 
Aβ-42 levels, and 2) to examine if these two variables were associated with a greater 
likelihood of HAND, and if there was a synergistic effect of FHD and CSF Aβ-42.
 2. MATERIALS AND METHOD
 Participants
This study included a convenience sample of 183 individuals with confirmed HIV disease 
who were enrolled in the larger multisite CNS HIV Antiretroviral Therapy Effects Research 
(CHARTER) study at one of six US academic medical centers. This study received approval 
from each institution’s ethical standards committee and all subjects received informed 
consent prior to participation. We identified 90 HIV+ individuals with a FHD and then 
selected a sample of 93 HIV+ individuals without FHD who were comparable to the FHD 
group on demographic factors (i.e., age, education, sex and ethnicity) and all HIV disease 
factors (e.g., nadir CD4+ T-cell count, plasma viral load, ART use, AIDS diagnosis). All 
participant selection was done blinded to NC functioning, HAND diagnosis, and research 
biomarker concentrations.
Participants completed a comprehensive neuropsychological, neuromedical, and psychiatric 
examination. This study excluded those with severe comorbid psychiatric, medical, and 
neurological conditions that would negatively affect neurocognitive functioning and thus 
prevent a HAND diagnosis (i.e., subjects rated as “confounding” [6]), thus including only 
those subjects rated as having either “contributing” or “incidental” conditions. For this study 
participants were also excluded if they were not currently taking antiretrovirals (ARVs), as 
treatment status may affect/obscure the associations among biomarkers and HAND.
 Procedure
 Family History of Dementia Determination—We coded persons as FHD positive if 
they reported that a first-degree (biologic parent, sibling, or offspring) or second-degree (i.e., 
biologic grandparent, grandchild, uncle, aunt, nephew, niece, half-sibling) relative was 
diagnosed with “dementia” or AD. When participants were unable to provide all of this 
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information, they were coded as not having FHD to avoid overestimation. Participants who 
were adopted and could not provide information about their family history were excluded 
[24].
 NC Assessment—All participants completed a comprehensive NC battery that 
assessed seven domains commonly affected by HIV [25]: verbal fluency, executive 
functions, speed of information processing, visual and verbal learning, visual and verbal 
recall (i.e., memory), working memory, and motor skills. This battery is the consensus NC 
battery for the CHARTER study and is widely used across the HIV Neurobehavioral 
Research Program [6].
Raw NC test scores were converted into T-scores (standard scores with a mean of 50 and SD 
of 10) using demographically adjusted norms to control for the effects of age, education, 
gender, and where available ethnicity [26 – 28]. Trained clinical neuropsychologists then 
used these demographically corrected T-scores to assign clinical ratings based on a highly 
specified algorithm described elsewhere [29], which were also discussed in a case 
conference format to determine HAND diagnoses using the accepted published guidelines 
for diagnosing HAND for research purposes (i.e., Frascati criteria [25]). Similar methods 
were also used to determine impairment in each neurocognitive domain. Thus, outcomes 
included impairment in each of the seven domains (impaired vs. NC normal) and HAND 
(any form of HAND vs. NC normal). These binary categorical variables were used in 
analyses.
 Neuromedical and Psychiatric Evaluation—The following information was 
gathered during the neuromedical assessment: medical history, current medications and 
medication history, neurological examination, physical examination, and laboratory 
evaluations (e.g., blood and cerebrospinal fluid collected for banking and testing). Lifetime 
substance dependence diagnoses were assessed via the computer-assisted Composite 
International Diagnostic Interview, version 2.1 [30], which included any past diagnosis of 
dependence for the following substances: amphetamine (including methamphetamine), 
cocaine, hallucinogen, inhalant, sedative, opioid, PCP, alcohol, and marijuana.
 Biomarker Assessment—CSF Aβ-42 was measured using a commercial suspension 
array immunoassay (EMD Millipore, Billerica, MA). HIV RNA levels were measured in 
blood and CSF by reverse transcriptase-polymerase chain reaction (RT-PCR, lower limit of 
quantitation 50 copies/mL) (Roche, Nutley, NJ). CD4+ T-cells were counted by flow 
cytometry. Other analytes were measured by routine methods in CLIA-certified clinical 
laboratories.
 Statistical Analyses
All statistical testing was two-sided and done at the 5% significance level. CSF Aβ-42 and 
plasma HIV RNA concentration were log10 transformed, as they were not normally 
distributed. Preliminary analyses (chi-square analyses or independent samples t-tests when 
appropriate) were conducted to determine whether any demographic or physical health 
variables differed at p < 0.05 between those with and without HAND and should thus be 
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considered as covariates, and also to determine whether FHD and Aβ-42 were associated 
with HAND at the bivariate level. We also examined whether CSF Aβ-42 concentrations 
differed between those with and without FHD using independent samples t-tests. Final 
preliminary bivariate analyses were conducted between both CSF Aβ-42 levels and FHD 
with the Table 1 variables to further determine any potential covariates (criteria p < 0.05). 
Primary analyses included multivariable logistic regressions including relevant covariates, 
FHD, and CSF Aβ-42, and their interactions with HAND and domain specific impairment as 
the dependent variables. The minimum Akaike Information Criterion (AIC) was used to 
determine the optimal set of predictors to be entered in the final logistic regressions. To 
investigate effects of CSF Aβ-42 levels and FHD on neurocognitive performance over time, 
survival analysis using Cox proportional hazard (PH) regression was applied. Specifically, 
we measured time (months) from baseline and the visit where neurocognitive decline was 
determined and regressed it on baseline levels of CSF Aβ-42. Decline was determined based 
on those who had any neurocognitive decline over the study period using published [31], 
regression-based norms. Briefly, z-scores were created for each for the 15 
neuropsychological measures based on normative data, and then these were averaged to 
create a summary regression change score. Additionally, the interaction between CSF Aβ-42 
and FHD on HAND over time was investigated. Effect size of CSF Aβ-42 (Hazard Ratio 
[HR]) in Cox PH models was estimated as hazard ratio for 1 unit increase in log-transformed 
values of CSF Aβ-42. A statistically significant HR below 1 means that higher values of 
CSF Aβ-42 are associated with lower risk of decline over time, or equivalently, that lower 
values of CSF Aβ-42 are associated with higher risk of decline over time.
 3. RESULTS
The HAND group and the NC normal group were similar on all potential covariate variables 
except comorbidity rating, with the NC normal group having a significantly higher 
proportion of incidental comorbidities (p = 0.02) (Table 1). Individuals with HAND had 
significantly lower levels of CSF Aβ-42 (p = 0.03) (Table 1), as did non-white subjects (p = 
0.007). No other Table 1 variables were associated with CSF Aβ-42. As the FHD groups 
were matched, there were no significant differences on any variables in Table 1 between 
those with and without a FHD (all p-values > 0.10). Those with HAND had a higher 
prevalence of FHD (52%) than those who were NC normal (45%), but this difference was 
not significant (p = 0.24). There was also no significant association between FHD status and 
CSF Aβ-42 concentrations (p = 0.89).
Forward stepwise multivariable logistic regression was conducted with HAND entered as the 
dependent variable and comorbiditiy rating (i.e., incidental vs. contributing), CSF Aβ-42, 
FHD, race, and the FHD X CSF Aβ-42 interaction as independent variables. Using the 
minimum AIC value to determine the optimal set of predictors to be entered in the final 
logistic regression, all predictors were retained except race. The overall model was 
significant (df = 4, χ2 = 14.14, p = 0.01) and there was a significant main effect of CSF 
Aβ-42 (p = 0.03) as well as a trend-level interaction between FHD and CSF Aβ-42 (p = 
0.06). Specifically, higher CSF Aβ-42 was only associated with lower odds of HAND in the 
FHD group (OR = 0.04, CI = 0.003 – 0.37, p < 0.01) compared to the no FHD group (OR = 
0.79, CI = 0.09 – 7.33, p = 0.83). Post-hoc power estimates for this primary model 
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predicting HAND from comorbidity rating, CSF Aβ-42, FHD, and FHD × CSF Aβ-42 
interaction were conducted using bootstrap method with 5000 replications. Based on the 
observed effects reported above, and assuming significance level of 0.05, the model had 45% 
power to detect a significant interaction, 80% power to detect a significant effect of CSF 
Aβ-42 within each group (FHD and no FHD), and 17% power to detect a significant 
difference in log-odds of HAND between FHD and no FHD groups.
The associations between FHD and HAND were not strengthened when examining 
inheritance type (maternal vs. paternal), type of dementia (AD vs. non-AD), or number of 
relatives with a dementia diagnosis. Furthermore, while age was not associated with any of 
our variables of interest (i.e., FHD, CSF Aβ-42, HAND), we forced this variable in as a 
covariate in the prior model, and the results remained unchanged. For visual representation 
of this interaction, a median split was conducted on raw CSF Aβ-42 values to create high 
and low CSF Aβ-42 groups (median = 573.7) and a CSF Aβ-42 by FHD four-group graph 
was created, which shows that individuals with low CSF Aβ-42 and FHD had the highest 
prevalence of HAND (74%), while the prevalence in the other three groups was similar (high 
CSF Aβ-42 FHD: 49%; high CSF Aβ-42 no FHD: 52%; low CSF Aβ-42 no FHD: 57%) 
(Figure 1).
Post-hoc analyses examined domain impairment using identical independent variables as in 
the previous models and revealed the following associations: working memory (trend for 
CSF Aβ-42, p = 0.07); verbal (FHD significant main effect, p = 0.03); executive functioning 
(CSF Aβ-42 significant main effect, p = 0.03); speed of information processing (CSF Aβ-42 
by FHD interaction, p = 0.01); memory (trend for FHD, p = 0.06); learning and motor (no 
associations with FHD or CSF Aβ-42). Most associations were in the expected direction, 
such that those with HAND had lower levels of CSF Aβ-42 or higher prevalence of FHD 
than those who were NC normal for each domain, except for an anomalous memory domain 
finding, where those with FHD had a lower prevalence of impairment.
In order to examine the predictive value of CSF Aβ-42 and FHD on cognitive trajectory 
(decline versus stable), a post-hoc survival analysis was conducted with 64 subjects who had 
available longitudinal neurocognitive data and met the criteria of having between 4–7 study 
visits. The range of time between baseline and the visit in which trajectory was determined 
was between 5 – 52 months (M = 31.2, SD = 12.8) and 11 of the 64 experienced a decline in 
neurocognitive performance while the remaining 53 remained stable. Note that the 64 
subjects with longitudinal data did not significantly differ from those without longitudinal 
data on any Table 1 variables (all p-values > 0.05). The survival analysis supported our 
cross-sectional main findings such that those who had higher baseline CSF Aβ-42 
concentrations were at lower risk of neurocognitive decline over time (HR = 0.03, 95% CI = 
0.001 – 0.58, p = 0.02). While we did not find an FHD X CSF Aβ-42 interaction (p = 0.83), 
when conducted separately in those with and without FHD survival analysis showed that 
lower CSF Aβ-42 was associated at the trend level with cognitive decline in the FHD group 
(HR = 0.02, 95% CI = 0.0001 – 1.51, p = 0.08) compared to the no FHD group (HR = 0.04, 
95% CI = 0.0004 – 3.37, p = 0.15).
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The goal of this study was to examine the relationships between FHD, levels of Aβ-42 in 
CSF, and HAND in a sample of adults with HIV on ART. Consistent with the aging 
literature (and some HIV studies [20 – 21], cf. [32]), we found that those with worse NC 
function (i.e., HAND) had lower CSF Aβ-42 levels. When examined together, our 
multivariable models confirmed that lower CSF Aβ-42 levels were significantly associated 
with higher odds of HAND, and also revealed that FHD moderated the effect of CSF Aβ-42 
on odds of HAND at the trend level. Specifically, CSF Aβ-42 was only associated with 
HAND in those who had FHD, with those with both FHD and low CSF Aβ-42 having the 
highest prevalence of HAND at 74% compared to those without FHD and those with FHD 
and high CSF Aβ-42 levels (HAND proportions ranging from 49% - 57%). Further 
exploration of the interaction trend in HAND on domain impairment showed a significant 
interaction on speed of information processing impairment suggesting that this domain may 
have been driving the initial interaction that approached significance with HAND and that 
perhaps this cognitive domain is more sensitive to amyloid-associated alterations than other 
domains. Contrary to our hypotheses, we found that those with and without FHD did not 
differ in CSF Aβ-42 concentrations and a statistically higher prevalence of HAND was not 
found in those with FHD. Furthermore, consistent with the literature on higher incidence of 
AD [33] and pathological Aβ-42 levels in African Americans [34], we found that non-white 
subjects (who were majority African American) had lower CSF Aβ-42 levels than white 
subjects.
These findings support the idea of using a combined approach of family history and 
biomarkers to identify those HIV+ individuals who may be at risk for cognitive decline and 
impairment. Our post-hoc longitudinal analysis supported our primary cross-sectional 
findings, such that higher baseline CSF Aβ-42 concentrations were associated with lower 
odds of neurocognitive decline. In the classic amyloidogenic pathology of AD, CSF 
biomarkers are important clinical tools that have been used as prognostic indicators [35]. 
Studies have shown that AD patients with low CSF Aβ-42 have worse clinical outcomes, 
quicker dementia progression, worse response to cholinesterase inhibitor treatment and 
greater mortality [36], and that CSF Aβ-42 alterations may be a precursor to future cognitive 
decline in those without initial impairment [37, 38]. It was interesting that CSF Aβ-42 was 
only associated with impairment in those with FHD despite there being no significant 
association between FHD and CSF Aβ-42 levels. This highlights the complex relationships 
of biomarkers in the prediction of NC impairment in HIV. It may be that those with FHD 
have some other underlying neuropathology that is explained by biomarkers we did not 
examine in the current study that makes them more susceptible to the effects of pathological 
(low) CSF Aβ-42 levels. In other words, those without FHD may have a higher “cognitive 
reserve” to tolerate amyloid deposition before presentation of neurocognitive impairment.
Most of our findings followed the directions of our hypotheses based on the literature. The 
lack of association between FHD and CSF Aβ-42 may be an artifact of the self-report nature 
of our FHD variable. Perhaps underreporting of FHD incidence due to a participants’ lack of 
knowledge about familial diagnoses resulted in less utility of this variable. Nonetheless, we 
still had an adequate sample size of those with and without FHD, and further analysis 
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revealed that even focusing on inheritance type (maternal vs. paternal), type of dementia 
(AD vs. non-AD), or number of family members with a diagnosis did not improve the utility 
of FHD. This is in contrast to studies that have shown that abnormal biomarker 
concentrations (particularly Aβ-42) are more likely in patients who have a family history of 
AD particularly via maternal inheritance [39]. While future research should determine FHD 
in a more objective format, perhaps via confirmation with clinicians of family members, this 
study and others [24] provide support for the use of self-report FHD as an easy to gather and 
inexpensive proxy for familial risk/genotype for dementia.
Limitations of this study include the cross-sectional nature of the primary analyses, 
preventing causal ascertainments to be made regarding the predictive value of Aβ-42 and 
FHD on cognitive decline over time. Furthermore, while the subjects in our post hoc 
longitudinal analysis were similar to those without longitudinal data, supporting the 
generalizability of these findings, our longitudinal analysis only included a small subset of 
subjects with available data. Nonetheless, these findings support longitudinal studies in the 
non-HIV literature demonstrating that abnormal biomarker changes precede NCI [37]. The 
relatively young age of our sample may have also influenced our findings. Older adults 
would not only be more susceptible to age-related neuropathology but would also have older 
parents and other relatives who would be more likely to have developed dementia. 
Nonetheless, the findings from this study provide several insights into identifying a CSF 
profile of NCI in HIV. Specifically, the Aβ-42 abnormalities seen in NCI in HIV seem to 
mirror those seen in other neurodegenerative diseases such as AD and we also provide 
evidence for the utility of FHD as a moderator of biomarkers on NCI in HIV. While it may 
perhaps be that HIV disease characteristics and biomarkers are more influential to NCI than 
traditional aging biomarkers, the interplay between these factors warrants further 
investigation, with the ultimate goal of isolating factors that may signal those patients at risk 
for incident neurocognitive impairment or future neurocognitive decline.
 5. CONCLUSION
In conclusion, this study provides support for the relevance of FHD in influencing biomarker 
associations with neurocognitive outcomes in HIV, particularly Aβ-42 and speed of 
information processing impairment. The inconsistency of the association of CSF Aβ-42 and 
NCI in the HIV literature may be partially explained by considering this biomarker in the 
context of other risk factors, such as FHD. Future research is warranted to further examine 
Aβ-42 and other biomarkers (e.g., neurofilament light chain) on incident neurocognitive 
impairment and longitudinal cognitive trajectories as individuals age with HIV.
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FHD, Aβ-42, and HAND
Notes. Aβ-42=amyloid beta 42; FHD=family history of dementia; HAND=HIV-associated 
neurocognitive disorder. Low and high Aβ-42 determined by median split (median = 573.7). 
*Omnibus p = 0.07; Low Aβ-42 FHD vs. High Aβ-42 no FHD: p = 0.03; Low Aβ-42 FHD 
vs. Low Aβ-42 no FHD: p = 0.08; Low Aβ-42 FHD vs. High Aβ-42 FHD: p = 0.01; High 
Aβ-42 FHD vs. High Aβ-42 no FHD: p = 0.75; High Aβ-42 FHD vs. Low Aβ-42 no FHD: p 
= 0.42; High Aβ-42 no FHD vs. Low Aβ-42 no FHD: p = 0.64.
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Table 1
Demographics, Clinical Characteristics, FHD, and Biomarkers by HAND (N=183)
HAND (n = 106) NC Normal (n = 77)
Variable M (SD) or No. (%) M (SD) or No. (%) p-value
Age 43.4 (8.2) 44.4 (7.4) 0.43
Gender, No. (%) Men 86 (81%) 59 (77%) 0.46
Education 13.0 (2.1) 13.1 (2.5) 0.84
Race, No. (%) White* 55 (52%) 41 (53%) 0.86
AIDS, No. (%) 80 (75%) 56 (73%) 0.67
Current CD4+ T-Cell Count (cells/μL) 460.0 (319.4) 461.5 (283.6) 0.73
Nadir CD4+ T-Cell Count (cells/μL) 163.4 (167.6) 159.5 (138.2) 0.67
Plasma Viral Load† (copies/mL) 2.3 (0.90) 2.4 (1.1) 0.92
Plasma Viral Load, No. (%) UD 56 (53%) 43 (56%) 0.69
No. (%) w/HCV co-infection 25 (24%) 23 (30%) 0.36
No. (%) w/Lifetime Substance Dependence Dx 51 (48%) 46 (60%) 0.12
CSF Aβ-42 (pg/mL) 624.1 (314.3) 691.4 (291.0) 0.03
No. (%) w/FHD 55 (52%) 35 (45%) 0.24
HAND Diagnoses
 No. (%) ANI 79 (75%) --
-- No. (%) MND 19 (18%) --
 No. (%) HAD 8 (8%) --
CHARTER Comorbidity Rating
 No. (%) Contributing 48 (45%) 22 (29%)
0.02
 No. (%) Incidental 58 (55%) 55 (71 %)
Notes. CSF = cerebrospinal fluid; FHD = family history of dementia; HCV = Hepatitis C virus; NC = neurocognitively; UD = undetectable.
*
For HAND, 35 black, 13 Hispanic, and 3 reported “other”; for NC Normal, 30 black and 6 Hispanic.
†
For plasma viral load log values are reported.
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